Pharmacokinetics and dosage adjustment in patients with hepatic dysfunction

Area of Science:

• Pharmacology
• Hepatology
• Drug Metabolism

Background:

• The liver is central to drug pharmacokinetics, influencing clearance, distribution, and elimination.
• Liver dysfunction, including cirrhosis, alters drug metabolism (CYP450, glucuronidation) and protein binding.
• Portal-systemic shunting in cirrhosis reduces first-pass metabolism, increasing oral drug absorption.

Purpose of the Study:

• To review the impact of liver dysfunction on drug pharmacokinetics and elimination.
• To discuss the challenges in adjusting drug dosages for patients with hepatic impairment.
• To highlight the limitations of current liver function tests in guiding drug therapy.

Main Methods:

• Literature review of drug pharmacokinetics in liver disease.
• Analysis of drug metabolism pathways affected by hepatic dysfunction.
• Evaluation of existing liver function tests and scoring systems (e.g., Child-Pugh).

Main Results:

• Liver dysfunction variably affects drug metabolism and clearance, with differential impacts on CYP450 enzymes and glucuronidation.
• Portal-systemic shunting significantly alters oral bioavailability of high-extraction drugs.
• Impaired renal function in advanced cirrhosis necessitates dose adjustments for renally eliminated drugs.
• Patients with liver cirrhosis exhibit altered sensitivity to certain drug classes (opioids, NSAIDs, beta-blockers, diuretics).

Conclusions:

• No simple endogenous marker reliably predicts hepatic drug elimination capacity.
• Quantitative liver function tests have not achieved widespread clinical use for drug dosage adjustment.
• The Child-Pugh score provides only rough guidance due to its lack of sensitivity.
• Further research is needed to develop more sensitive liver function tests for precise drug dosage adjustments in hepatic dysfunction.